NAD augmentation as a disease-modifying strategy for neurodegeneration

Nicotinamide adenine dinucleotide (NAD) augmentation is a multi-target therapeutic approach that impacts on multiple disease pathways across neurodegenerative diseases (NDDs). 

NAD augmentation shows strong preclinical evidence of benefit in several NDDs.

Early-phase clinical trials show encouraging results regarding target engagement and preliminary efficacy in several NDDs.

Current data indicate that NAD augmentation therapy is safe, but long-term data in appropriately sized cohorts are not yet available.

The number of clinical trials testing NAD augmentation in NDDs is rising rapidly, but long-term, well-planned, and adequately powered efficacy trials are urgently needed.

https://www.cell.com/trends/endocrinology-metabolism/fulltext/S1043-2760(25)00070-0

https://sciencemission.com/NAD-augmentation-and-neurodegeneration